Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood CD19-BCMA CAR-T cells
- Development stage
- Phase 2
- Lead developer
- Beijing Gaobo Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Umbilical cord blood CD19-BCMA CAR-T cells** are an investigational, donor-derived dual-target chimeric antigen receptor T-cell product generated from umbilical cord blood T cells. The engineered cells are designed to recognize **CD19** on B cells and **B-cell maturation antigen** on plasmablasts and plasma cells, enabling CAR-mediated depletion of pathogenic B-cell-lineage compartments. Beijing GoBroad Hospital is evaluating this treatment in a single-center Phase 1/2 study for refractory lupus nephritis, systemic sclerosis, and primary Sjogren syndrome with pulmonary hypertension. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947473))
- Other names
- cord blood CD19-BCMA CAR-T cell therapyumbilical cord blood CD19-BCMA CAR T cell therapyumbilical cord blood CD19-BCMA CAR-T cellsumbilical cord blood CD19BCMA CAR T cell therapy
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on umbilical cord blood CD19-BCMA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood CD19-BCMA CAR-T cells.